Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis

Cited by (1,004)

Items 601–700 of 1,004

1. Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges
   Muhammad Imran Ahmad, Muhammad Umair Khan, Sudha Kodali, Akshay Shetty, Suzanne M. Bell, David W. Victor · 2022 · Journal of Hepatocellular Carcinoma
2. Prevalence of hepatic steatosis as assessed by controlled attenuation parameter (CAP) in subjects with metabolic risk factors in primary care. A population-based study
   Núria Fabrellas, Rosario Hernández, Isabel Graupera, Elsa Solà, P. Montes Ramos, N. Martin, Gemma Sáez, Consuelo Simón, Almudena Pérez, Teresa Graell et al. · 2018 · PLoS ONE
3. Mitochondria Matter: Systemic Aspects of Nonalcoholic Fatty Liver Disease (NAFLD) and Diagnostic Assessment of Liver Function by Stable Isotope Dynamic Breath Tests
   Agostino Di Ciaula, Giuseppe Calamita, Harshitha Shanmugam, Mohamad Khalil, Leonilde Bonfrate, David Q.‐H. Wang, György Baffy, Piero Portincasa · 2021 · International Journal of Molecular Sciences
4. Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality
   Stefano Ballestri, Alessandro Mantovani, Maria Di Girolamo, Enrica Baldelli, Mariano Capitelli, Amedeo Lonardo · 2023 · Metabolism and Target Organ Damage
5. Liver stiffness progression in biopsy-proven metabolic dysfunction–associated steatotic disease among people with diabetes versus people without diabetes: A prospective multicenter study
   Daniel Q. Huang, Laura Wilson, Cynthia A. Behling, Maral Amangurbanova, David Erwin Kleiner, Kris V. Kowdley, Srinivasan Dasarathy, Norah A. Terrault, Anna Mae Diehl, Naga Chalasani et al. · 2024 · Hepatology
6. Early Obesity
   Valeria Cuzmar, Gigliola Alberti, Ricardo D. Uauy, Ana Paula Rodrigues Pereira, Cristián García, Florencia De Barbieri, Camila Corvalán, José Luis Santos, Verónica Mericq G, Luis Antonio Villarroel et al. · 2019 · Journal of Pediatric Gastroenterology and Nutrition
7. Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus–Associated Nonalcoholic Fatty Liver Disease
   Lindsay T. Fourman, Takara Leah Stanley, Isabel Zheng, Chelsea S. Pan, Meghan N. Feldpausch, Julia Purdy, Julia Aepfelbacher, Colleen G. Buckless, Andrew Tsao, Kathleen E. Corey et al. · 2020 · Clinical Infectious Diseases
8. Non-alcoholic fatty liver diseases: current challenges and future directions
   Elke Roeb · 2021 · Annals of Translational Medicine
9. PNPLA3 and TM6SF2 polymorphisms in Brazilian patients with nonalcoholic fatty liver disease
   Quelson Coelho Lisboa, Mateus Jorge Nardelli, Patrícia de Araújo Pereira, Débora Marques de Miranda, Stephanie Nunes Ribeiro, Raíssa Soares Neves da Costa, Camila Azevedo Versiani, Paula Vieira Teixeira Vidigal, Teresa Cristina Abreu Ferrari, Cláudia Alves Couto · 2020 · World Journal of Hepatology
10. Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET‐NASH Study
    Alfred Sidney Barritt, Stephanie E. Watkins, Norman Gitlin, Samuel Klein, Anna Suk-Fong Lok, Rohit Seth Loomba, Cheryl Schoen, K. Rajender Reddy, Huy Ngoc Trinh, Andrea R. Mospan et al. · 2021 · Hepatology Communications
11. Fatty Liver Through the Ages: Nonalcoholic Steatohepatitis
    Zobair M. Younossi, Linda L Henry · 2021 · Endocrine Practice
12. Transcriptomic profiling of a multiethnic pediatric NAFLD cohort reveals genes and pathways associated with disease
    Kangning Yao, Elena Tarabra, Daniela Sia, Raffaella A. Morotti, Rima L. Fawaz, Pamela L. Valentino, Nicola Santoro, Sonia Caprio, Silvia Liu, Dean Yimlamai · 2022 · Hepatology Communications
13. Does aerobic exercise reduce NASH and liver fibrosis in patients with non-alcoholic fatty liver disease? A systematic literature review and meta-analysis
    Veera Houttu, Julia Bouts, Yasaman Vali, Joost G. Daams, Aldo Grefhorst, Max Nieuwdorp, Adriaan Georgius Holleboom · 2022 · Frontiers in Endocrinology
14. Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
    Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima · 2022 · Clinical and Molecular Hepatology
15. Diagnostic comparison of vibration-controlled transient elastography and MRI techniques in overweight and obese patients with NAFLD
    Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Takaomi Kessoku, Yasushi Honda, Yuji Ogawa, Kento Imajo, Takuma Higurashi, Kunihiro Hosono et al. · 2022 · Scientific Reports
16. Too much medicine: overdiagnosis and overtreatment of non-alcoholic fatty liver disease
    Ian A.C. Rowe · 2017 · The Lancet. Gastroenterology & hepatology
17. Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD
    Moolla, Ahmad, Poolman, Toryn, Othonos, Nantia, Dong, Jiawen, Smith, Kieran, Cornfield, Thomas, White, Sarah, Ray, David W., Mouchti, Sofia, Mózes, Ferenc E. et al. · 2025 · JHEP Reports
18. Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso)
    Rodrigo O. Moreira, Cynthia Melissa Valério, Cristiane Alves Villela‐Nogueira, Cíntia Cercato, Fernando Gerchman, Ana Maria Lottenberg, Amélio F. Godoy‐Matos, Ricardo de Andrade Oliveira, Carlos Eduardo Brandão‐Mello, Mário Reis Álvares‐da‐Silva et al. · 2023 · Archives of Endocrinology and Metabolism
19. Platelet, Antiplatelet Therapy and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review
    A. Boccatonda, Lorenza Del Cane, Lara Marola, D. D'Ardes, Gianfranco Lessiani, Nicoletta di Gregorio, Claudio Ferri, Francesco Cipollone, C. Serra, Francesca Santilli et al. · 2024 · Life
20. A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action
    Shiqin Zhang, Xiaoling Ren, Bingzheng Zhang, Tian Lan, Bing Liu · 2024 · Molecules
21. Effects of Resmetirom on Metabolic‐Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon‐Like Peptide‐1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO ‐ NASH Trial
    Mazen Noureddin, Mary Eugenia Rinella, Rebecca A. Taub, Dominic Labriola, Raul C. Camacho, Naim Alkhouri, Rohit Seth Loomba, Meena B. Bansal · 2025 · Alimentary Pharmacology & Therapeutics
22. The association of non-alcoholic fatty liver disease and atrial fibrillation: a review
    Aki Juhani Käräjämäki, Janne Hukkanen, Olavi H. Ukkola · 2018 · Annals of Medicine
23. Magnetic-Assisted Treatment of Liver Fibrosis
    Kateryna V. Levada, Alexander S. Omelyanchik, Valeria V. Rodionova, Ralf Weiskirchen, Matthias Bartneck · 2019 · Cells
24. Association of Serum Homocysteine Levels with Histological Severity of NAFLD
    Yilun Xu, Yaqi Guan, Xingyi Yang, Ziqiang Xia, Jinming Wu · 2020 · Journal of Gastrointestinal and Liver Diseases
25. Coupling Machine Learning and Lipidomics as a Tool to Investigate Metabolic Dysfunction-Associated Fatty Liver Disease. A General Overview
    Helena Castañé, Gerard Baiges‐Gayà, Anna Hernández‐Aguilera, Elisabet Rodríguez‐Tomàs, Salvador Fernández‐Arroyo, Pol Herrero, Antoni Delpino-Rius, Núria Canela-Canela, Javier Abel Menéndez, Jordi Camps et al. · 2021 · Biomolecules
26. Non-invasive assessment of fibrosis and steatosis in pediatric non-alcoholic fatty liver disease
    Bryan R. Chen, Calvin Q. Pan · 2021 · Clinics and Research in Hepatology and Gastroenterology
27. Nonalcoholic steatohepatitis: global impact and clinical consequences
    Khaled W. Kabbara, Pegah Golabi, Zobair M. Younossi · 2021 · Endocrine Connections
28. Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease
    Eda Kaya, Yusuf Nadir Yilmaz · 2022 · Therapeutic Advances in Endocrinology and Metabolism
29. NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care
    Piero Portincasa · 2023 · Internal and Emergency Medicine
30. Risk of Severe Infection in Patients With Biopsy-proven Nonalcoholic Fatty Liver Disease – A Population-based Cohort Study
    Fahim Ebrahimi, Tracey G. Simon, Hannes Hagström, Jonas K. Söderling, Axel Wester, Björn Roelstraete, Jonas Filip Ludvigsson · 2023 · Clinical Gastroenterology and Hepatology
31. Mouse strain-dependent variation in metabolic associated fatty liver disease (MAFLD): a comprehensive resource tool for pre-clinical studies
    Hamzeh Karimkhanloo, Stacey N. Keenan, Jacqueline A. Bayliss, William De Nardo, Paula Michelle Miotto, Camille J. Devereux, Shuai Nie, Nicholas A. Williamson, Andrew Ryan, Matthew J. Watt et al. · 2023 · Scientific Reports
32. Spatial and Single‐Cell Transcriptomics Reveals the Regional Division of the Spatial Structure of MASH Fibrosis
    Jinzhong Li, Jin-zhong Li, YE Li-hong, Li Ni, Xin Huang, Xujing Liang, Hai-cong Zhang, Zhiquan Liu, Xuedong Zhang, Yunyan Liu et al. · 2024 · Liver International
33. Hepatic stellate cell heterogeneity: Functional aspects and therapeutic implications
    Yana Geng, Robert F. Schwabe · 2025 · Hepatology
34. Metabolic profiles and fibrosis of nonalcoholic fatty liver disease in the elderly: A community‐based study
    Tsung‐Po Chen, Michelle Lai, Wen‐Yuan Lin, Kuo‐Chin Huang, Kuen‐Cheh Yang · 2020 · Journal of Gastroenterology and Hepatology
35. NAFLD in type 2 diabetes mellitus: Still many challenging questions
    Simona Cernea, Itamar Raz · 2020 · Diabetes/Metabolism Research and Reviews
36. Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV
    Maurice Michel, Christian Labenz, Alisha Wahl, Malena Anders, Angelo Armandi, Yvonne Huber, Peter R. Galle, Martin Sprinzl, Jörn Markus Schattenberg · 2022 · AIDS
37. Hepatic steatosis and advanced hepatic fibrosis are independent predictors of long‐term mortality in acute myocardial infarction
    Yip Han Chin, Jieyu Lim, Gwyneth Kong, Cheng Han Ng, Rachel Jia Ling Goh, Mark Dhinesh Muthiah, Anurag Mehta, Bryan Chong, Chaoxing Lin, Kai En Chan et al. · 2022 · Diabetes Obesity and Metabolism
38. Low 25 (OH) vitamin D levels are associated with increased prevalence of nonalcoholic fatty liver disease and significant liver fibrosis
    Stefano Ciardullo, Emanuele Muraca, Rosa Cannistraci, Silvia Perra, Guido Lattuada, Gianluca Perseghin · 2023 · Diabetes/Metabolism Research and Reviews
39. Hepatic Outcomes of Nonalcoholic Fatty Liver Disease Including Cirrhosis and Hepatocellular Carcinoma
    Saleh A. Alqahtani, Wah‐Kheong Chan, Ming‐Lung Yu · 2023 · Clinics in Liver Disease
40. Long-Term Outcomes of Nonalcoholic Fatty Liver Disease: From Nonalcoholic Steatohepatitis to Nonalcoholic Steatofibrosis
    Zobair M. Younossi · 2017 · Clinical Gastroenterology and Hepatology
41. Role of two-dimensional shear wave elastography in chronic liver diseases: A narrative review
    Jae Yoon Jeong, Young Seo Cho, Joo Hyun Sohn · 2018 · World Journal of Gastroenterology
42. Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
    Yoshitaka Arase, Koichi Shiraishi, Kazuya Anzai, Hirohiko Sato, Erika Teramura, Kota Tsuruya, Shunji Hirose, Ryuzo Deguchi, Masao Toyoda, Tetsuya Mine et al. · 2019 · Clinical Drug Investigation
43. Exercise training improves serum biomarkers of liver fibroinflammation in patients with metabolic dysfunction‐associated steatohepatitis
    Harris, Sara J., Smith, Nataliya, Hummer, Breianna, Schreibman, Ian R., Faust, Alison J., Geyer, Nathaniel R., Chinchilli, Vernon M., Sciamanna, Chris, Loomba, Rohit, Stine, Jonathan G. · 2024 · Liver International
44. Association between depression and metabolic dysfunction-associated fatty liver disease/significant fibrosis
    Donghee Kim, Brittany Burns Dennis, George T. Cholankeril, Aijaz Ahmed · 2023 · Journal of Affective Disorders
45. The Liver in Heart Failure: From Biomarkers to Clinical Risk
    Nadia Aspromonte, Isabella Fumarulo, Lucrezia Petrucci, Bianca Biferali, Antonio Liguori, Antonio Gasbarrini, Massimo Massetti, Luca Miele · 2023 · International Journal of Molecular Sciences
46. Effect of phospholipid curcumin Meriva on liver histology and kidney disease in nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial
    Musso, Giovanni, Pinach, Silvia, Mariano, Filippo, Saba, Francesca, De Michieli, Franco, Framarin, Luciana, Berrutti, Mara, Paschetta, Elena, Parente, Renato, Lizet Castillo, Yanina et al. · 2025 · Hepatology
47. Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease
    Nobuharu Tamaki, Takefumi Kimura, Shun‐ichi Wakabayashi, Takeji Umemura, Namiki Izumi, Rohit Seth Loomba, Masayuki Kurosaki · 2024 · Alimentary Pharmacology & Therapeutics
48. MASLD: What We Have Learned and Where We Need to Go—A Call to Action
    Sedighe Hosseini Shabanan, Vitor F. Martins, Tanya J. Wolfson, Jake T. Weeks, Lael Ceriani, Cynthia A. Behling, Victoria Chernyak, Ahmed El Kaffas, Amir Ali Borhani, Aiguo Han et al. · 2024 · Radiographics
49. Dietary wheat amylase trypsin inhibitors promote features of murine non-alcoholic fatty liver disease
    Muhammad Ashfaq–Khan, Misbah Aslam, Muhammad Asif Qureshi, Marcel Senkowski, Shih Yen-Weng, Susanne Strand, Yong Ook Kim, Geethanjali Pickert, Jörn Markus Schattenberg, Detlef Schuppan · 2019 · Scientific Reports
50. Multiparametric MR Is a Valuable Modality for Evaluating Disease Severity of Nonalcoholic Fatty Liver Disease
    Young‐Sun Lee, Yang Jae Yoo, Young Kul Jung, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, In Hee Kim, Soo Yeon Lee, Baek‐hui Kim, Jeong Woo Kim et al. · 2020 · Clinical and Translational Gastroenterology
51. Human Fibrosis: Is There Evidence for a Genetic Predisposition in Musculoskeletal Tissues?
    Louis Dagneaux, Aaron R. Owen, Jacob W. Bettencourt, Jonathan D. Barlow, Peter C. Amadio, Jean Pierre A. Kocher, Mark E. Morrey, Joaquín Sánchez‐Sotelo, Daniel J. Berry, André J. van Wijnen et al. · 2020 · The Journal of Arthroplasty
52. Conventional ultrasound for diagnosis of hepatic steatosis is better than believed
    Christoph Frank Dietrich, Long Shi, Axel Löwe, Yi Dong, Andrej Potthoff, Zeno Adrian Sparchez, Andreas Teufel, Sabine Guth, Jonas Koch, Richard G Barr et al. · 2021 · Zeitschrift für Gastroenterologie
53. Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease
    Luca V. C. Valenti, Federica Pedica, Massimo Colombo · 2021 · Digestive and Liver Disease
54. The Utility and Diagnostic Accuracy of Transient Elastography in Adults with Morbid Obesity: A Prospective Study
    Ahmad Hassan Ali, Alhareth Al Juboori, Gregory F. Petroski, Alberto A. Diaz‐Arias, Majid Mufaqam Syed‐Abdul, Andrew A. Wheeler, Rama Ganga, James B. Pitt, Nicole Spencer, Ghassan M. Hammoud et al. · 2022 · Journal of Clinical Medicine
55. Nonalcoholic fatty liver disease and obstructive sleep apnea in women with polycystic ovary syndrome
    Iliana Doycheva, David A. Ehrmann · 2022 · Fertility and Sterility
56. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients : what do we know so far ?
    Quentin Binet, Audrey Loumaye, Vanessa Preumont, Jean‐Paul Thissen, Michel Paul Hermans, Nicolas Lanthier · 2022 · Acta gastro-enterologica belgica
57. Prevalence, characteristics, and mortality outcomes of obese and nonobese MAFLD in the United States
    Allen Dao, Vy H. Nguyen, Takanori Ito, Ramsey C Cheung, Mindie H. Nguyen · 2022 · Hepatology International
58. SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum
    Yoshihiro Kamada, Takahiro Nakamura, Satoko Isobe, Kumiko Hosono, Yukiko Suama, Yukie Ohtakaki, Arihito Nauchi, Naoto Yasuda, Soh Mitsuta, Kouichi Miura et al. · 2022 · Journal of Gastroenterology
59. Updated S2k clinical practice guideline on non-alcoholic fatty liver disease (NAFLD) issued by the German society of gastroenterology, digestive and metabolic diseases (DGVS)–April 2022–AWMF Registration No.: 021–025
    Authors, Collaborators: · 2022 · Zeitschrift für Gastroenterologie
60. The Association of Fibrosis-4 Index Scores with Severe Liver Outcomes in Primary Care
    Andrew D. Schreiner, William P. Moran, Jingwen Zhang, Sherry Livingston, Justin E. Marsden, Patrick D. Mauldin, David Koch, Mulugeta Gebregziabher · 2022 · Journal of General Internal Medicine
61. Endogenous sex hormones and nonalcoholic fatty liver disease in US adults
    Donghee Kim, Richie Manikat, George T. Cholankeril, Aijaz Ahmed · 2023 · Liver International
62. Lipotoxic hepatocyte derived LIMA1 enriched small extracellular vesicles promote hepatic stellate cells activation via inhibiting mitophagy
    Shihui Li, Fuji Yang, Cheng Ran Fang, Ling Zhu, Yongmin Yan · 2024 · Cellular & Molecular Biology Letters
63. Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?
    Tobias Puengel, Frank Tacke · 2024 · Expert Opinion on Pharmacotherapy
64. Cathepsin D is essential for the degradomic shift of macrophages required to resolve liver fibrosis
    Paloma Ruiz-Blázquez, María Fernández-Fernández, Valéria Pistorio, Celia Martínez–Sánchez, Michele Costanzo, Paula Iruzubieta, Ekaterina Zhuravleva, Júlia Cacho-Pujol, Sílvia Ariño, Alejandro del Castillo-Cruz et al. · 2024 · Molecular Metabolism
65. Non-invasive tests: Establishing efficacy for metabolic dysfunction–associated steatohepatitis beyond the biopsy—Current perspectives from the Division of Hepatology and Nutrition, US Food and Drug Administration
    Frank A. Anania, Rebecca Hager, Karen M. Higgins, George A. Makar, Jeffrey N. Siegel, Tram T. Tran · 2025 · Hepatology
66. Collagen Formation Assessed by N‐Terminal Propeptide of Type 3 Procollagen Is a Heritable Trait and Is Associated With Liver Fibrosis Assessed by Magnetic Resonance Elastography
    Cyrielle Caussy, Meera Bhargava, Ida Falk Villesen, Natasja Stæhr Gudmann, Diana Julie Leeming, M.A. Karsdal, Claire Faulkner, Denny Bao, Amy Liu, Min‐Tzu Lo et al. · 2019 · Hepatology
67. Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: Analysis of a French national hospital database
    Jérôme Boursier, Sanatan Shreay, Cécile Fabron, E. Torreton, Jeremy Fraysse · 2020 · EClinicalMedicine
68. The Natural History of NAFLD, a Community-Based Study at a Large Health Care Delivery System in the United States
    Lisa M. Nyberg, Craig T. Cheetham, Heather M. Patton, Su-Jau Yang, Kevin M. Chiang, Susan L. Caparosa, Julie A. Stern, Anders H. Nyberg · 2020 · Hepatology Communications
69. Head-to-head comparison of magnetic resonance elastography-based liver stiffness, fat fraction, and T1 relaxation time in identifying at-risk NASH
    Jiahui Li, Xin Lu, Zheng Hong Zhu, Kyle J. Kalutkiewicz, Taofic Mounajjed, Terry M. Therneau, Sudhakar Kundapur Venkatesh, Yi Sui, Kevin J. Glaser, Safa Hoodeshenas et al. · 2023 · Hepatology
70. Patients with stage 3 compared to stage 4 liver fibrosis have lower frequency of and longer time to liver disease complications
    Page D. Axley, Sandhya K. Mudumbi, Shabnam Sarker, Yong‐Fang Kuo, Ashwani Kumar Singal · 2018 · PLoS ONE
71. Magnetic resonance imaging of obesity and metabolic disorders: Summary from the 2019 ISMRM Workshop
    Peng Hu, Rosa T. Branca, Diego Hernando, Dimitrios C. Karampinos, Jürgen Machann, Charles A. McKenzie, Holden H. Wu, Takeshi Yokoo, S. Sendhil Velan · 2019 · Magnetic Resonance in Medicine
72. The role of the gut microbiome and exercise in non-alcoholic fatty liver disease
    Veera Houttu, Ulrika Boulund, Aldo Grefhorst, Maarten R. Soeters, Sara‐Joan Pinto‐Sietsma, Max Nieuwdorp, Adriaan Georgius Holleboom · 2020 · Therapeutic Advances in Gastroenterology
73. Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study
    Meryem Demir, Oğuzhan Deyneli, Yusuf Nadir Yilmaz · 2018 · The Turkish Journal of Gastroenterology
74. Accuracy of imaging methods for steatohepatitis diagnosis in non‐alcoholic fatty liver disease patients: A systematic review
    Giulia Besutti, Luca V. C. Valenti, Guido Ligabue, Maria Chiara Bassi, Pierpaolo Pattacini, Giovanni Guaraldi, Paolo Giorgi Rossi · 2019 · Liver International
75. Epidemiology, Pathogenesis, and Diagnostic Strategy of Diabetic Liver Disease in Japan
    Yoshio Sumida, Toshihide Shima, Yasuhide Mitsumoto, Takafumi Katayama, Atsushi Umemura, Kanji Yamaguchi, Yoshito Itoh, Masashi Yoneda, Takeshi Okanoue · 2020 · International Journal of Molecular Sciences
76. Advances in ultrasound elastography for nonalcoholic fatty liver disease
    Masato Yoneda, Yasushi Honda, Asako Nogami, Kento Imajo, Atsushi Nakajima · 2020 · Journal of Medical Ultrasonics
77. Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination
    Valentin Blank, David Petroff, Sebastian Beer, Albrecht Böhlig, Maria Heni, Thomas Berg, Yvonne Bausback, Arne Dietrich, Anke Tönjes, Marcus Hollenbach et al. · 2020 · Scientific Reports
78. Incidence of liver‐related morbidity and mortality in a population cohort of non‐alcoholic fatty liver disease
    Ville Männistö, Veikko V Salomaa, Martti A. Färkkilä, Antti Jula, Satu Männistö, Iris Erlund, Jouko Sundvall, Annamari Lundqvist, Markus Perola, Fredrik O. Åberg · 2021 · Liver International
79. Impact of the new definition of metabolic dysfunction–associated fatty liver disease on detection of significant liver fibrosis in US adolescents
    Stefano Ciardullo, Marco Carbone, Pietro Invernizzi, Gianluca Perseghin · 2022 · Hepatology Communications
80. Liver stiffness (Fibroscan®) is a predictor of all‐cause mortality in people with non‐alcoholic fatty liver disease
    Michael Rudi Braude, Stuart Keith Roberts, Ammar Majeed, John Samuel Lubel, Jirayut Prompen, Anouk T Dev, William Sievert, Stephen Bloom, Paul John Gow, William W. Kemp · 2022 · Liver International
81. The pharmacological management of NAFLD in children and adolescents
    Savinda Liyanagedera, Robert Patrick Williams, Silvio Veraldi, Valério Nobili, Jake Peter Mann · 2017 · Expert Review of Clinical Pharmacology
82. Insulin Resistance Is Central to Long-Term Reversal of Histologic Nonalcoholic Steatohepatitis After Metabolic Surgery
    Russo, Maria Francesca, Lembo, Erminia, Mari, Andrea, Angelini, Giulia, Verrastro, Ornella, Nanni, Giuseppe, Pompili, Maurizio, Raffaelli, Marco, Vecchio, Fabio Maria, Bornstein, Stefan R et al. · 2021 · The Journal of Clinical Endocrinology & Metabolism
83. The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysis
    Qiong Lv, Hua-Shan Zhao · 2024 · Annals of Medicine
84. NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic–Metabolic Interplay
    Simona Cernea · 2024 · Life
85. Liver histology is associated with long-term clinical outcomes in patients with metabolic dysfunction–associated steatohepatitis
    Zobair M. Younossi, Kamal Kant Mangla, Tina Landsvig Berentzen, Katrine Grau, Mette Skalshøi Kjær, Steen Ladelund, Louise Maymann Nitze, Crystal L. Coolbaugh, Chih-Yuan Hsu, Hannes Hagström · 2024 · Hepatology Communications
86. ALT levels, alcohol use, and metabolic risk factors have prognostic relevance for liver-related outcomes in the general population
    Ville Männistö, Veikko V Salomaa, Antti Jula, Annamari Lundqvist, Satu Männistö, Markus Perola, Fredrik O. Åberg · 2024 · JHEP Reports
87. Clinical Care Pathway for the Risk Stratification and Management of Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease
    Fasiha Kanwal, Fernando Bril, Vincent Wai‐Sun Wong, Leon A. Adams, Kim M. Pfotenhauer, NEIL SKOLNIK, Eugene E. Wright, Robert H. Eckel, Mazen Noureddin, Rohit Seth Loomba et al. · 2026 · Gastroenterology
88. Prescription of statins in suspected non‐alcoholic fatty liver disease and high cardiovascular risk, a population‐based study
    Eline H. van den Berg, Alba A. B. Wolters, Robin P. F. Dullaart, Han J. Moshage, David Zurakowski, Vincent Erwin de Meijer, Hans Blokzijl · 2019 · Liver International
89. Ultrasound Fatty Liver Indicator: A Simple Tool for Differentiating Steatosis From Nonalcoholic Steatohepatitis: Validity in the Average Obese Population
    Steve M. Nelson, Jason D. Hoskins, Christopher J. Lisanti, Jayanta Chaudhuri · 2019 · Journal of Ultrasound in Medicine
90. Effects of Laparoscopic Sleeve Gastrectomy on Non-Alcoholic Steatohepatitis and Liver Fibrosis in Japanese Patients with Severe Obesity
    Haruka Nikai, Kazuyuki Ishida, Akira Umemura, Shigeaki Baba, Hiroyuki Nitta, Tamotsu Sugai, Akira Sasaki · 2020 · Obesity Surgery
91. The Placebo Response in Randomized Trials in Nonalcoholic Steatohepatitis Simply Explained
    Ian A.C. Rowe, Richard Parker · 2021 · Clinical Gastroenterology and Hepatology
92. Racial differences in prevalence and severity of non-alcoholic fatty liver disease
    Maurizio Bonacini, Farah Kassamali, Swathi Kari, Nieves Lopez Barrera, Mohamed Kohla · 2021 · World Journal of Hepatology
93. Primary Care Providers and Nonalcoholic Fatty Liver Disease: A Needs Assessment Survey
    Kendall B. Islam, Danielle Brandman, Janet N. Chu, Max L. Goldman, Rena K. Fox · 2022 · Digestive Diseases and Sciences
94. Treatment options for nonalcoholic steatohepatitis - a safety evaluation
    Danny Issa, Julia J. Wattacheril, Arun Jayant Sanyal · 2017 · Expert Opinion on Drug Safety
95. Apixaban and Rosuvastatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease
    Rommel G. Tirona, Zahra Kassam, Ruth Strapp, Mala Ramu, Catherine Zhu, Melissa Liu, Ute I. Schwarz, Richard B. Kim, Bandar Al‐Judaibi, Melanie D. Beaton · 2018 · Drug Metabolism and Disposition
96. Prognostic nutritional index (PNI) and risk of non-alcoholic fatty liver disease and advanced liver fibrosis in US adults: Evidence from NHANES 2017–2020
    Ge Chen, Liqing Fan, Ting Yang, Tingting Xu, Zixuan Wang, Yan Wang, Lingling Kong, Xutong Sun, Kan Chen, Qing Xie et al. · 2024 · Heliyon
97. Oxymatrine alleviates high-fat diet/streptozotocin-induced non-alcoholic fatty liver disease in C57BL/6 J mice by modulating oxidative stress, inflammation and fibrosis
    Di Lou, Qing Fang, Yinghao He, Ruyu Ma, Xinyan Wang, Hanbing Li, Min-You Qi · 2024 · Biomedicine & Pharmacotherapy
98. Liver fibrosis as a barometer of systemic health by gauging the risk of extrahepatic disease
    Amedeo Lonardo, Stefano Ballestri, György Baffy, Ralf Weiskirchen · 2024 · Metabolism and Target Organ Damage
99. Impact of metabolic dysfunction severity in steatotic liver disease and its interaction with liver fibrosis on all-cause mortality and multiple hepatic and extra-hepatic outcomes
    Daniel James Cuthbertson, Oliver John Kennedy, Josh Bilson, Theresa Hydes, Giovanni Targher, Kate Glyn‐Owen, Ryan Malcolm Buchanan, Paul J. Roderick, Christopher D. Byrne · 2025 · Metabolism
100. Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management
     Mary Eugenia Rinella, Silvia C. Sookoian · 2026 · Nature Reviews Gastroenterology & Hepatology